131 patents currently held
15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2028. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Oct 2028
Next term end
58
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2034 · High confidence
Also notable
Ends Feb 2036 · High confidence
Also notable
Ends Feb 2041 · High confidence
Also notable
Ends Sep 2031 · High confidence
Also notable
Ends Aug 2031 · Medium confidence
Also notable
Ends Aug 2031 · High confidence
Also notable
Ends Aug 2037 · High confidence
Also notable
Ends May 2036 · High confidence
Combination of Vaccination and Inhibition of the PD-1 Pathway
US 9,974,845
Cited by 177 later US patents, top 1% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Artificial Nucleic Acid Molecules for Improved Protein Expression
US 11,149,278
Cited by 139 later US patents, top 1% of utility patents granted in 2021 in our data. Protection runs to 2036.
Coronavirus Vaccine
US 11,576,966
Cited by 26 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2041.
Nucleic Acids Comprising formula (NuGlXmGnNv)a and Derivatives Thereof as Immunostimulating Agent/Adjuvant
US 9,226,959
Cited by 275 later US patents, top 1% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Tumour Antigen
US 10,010,592
Cited by 164 later US patents, top 1% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Protein
US 9,234,013
Cited by 201 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Artificial Nucleic Acid Molecules Encoding a Norovirus Antigen and Uses Thereof
US 11,141,474
Cited by 77 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2037.
Dry Powder Composition Comprising Long-Chain RNA
US 10,517,827
Cited by 110 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2036.
Formerly held, still cited
Notable
Ends Jul 2036 · High confidence
Cited by 101 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2036.
now held by Curevac Manufacturing GmbH
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Dec 4 to 27, 2026 · next Dec 4
- 3 fees due Jan 4 to 11, 2027 · next Jan 4
- 3 fees due Feb 6 to 28, 2027 · next Feb 6
- 1 fee due Mar 19, 2027The maintenance fee for Artificial Nucleic Acid Molecules for Improved Protein Expression (US 11,761,009) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 4 fees due Apr 8 to 17, 2027 · next Apr 8
- 1 fee due Jun 30, 2027The maintenance fee for Dry Powder Composition Comprising Long-Chain RNA (US 10,517,827) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 3 fees due Jul 5 to 12, 2027 · next Jul 5
- 3 fees due Sep 5 to 24, 2027 · next Sep 5
- 4 fees due Oct 7 to 23, 2027 · next Oct 7
- 1 fee due Nov 7, 2027The maintenance fee for VACCINATION WITH mRNA-CODED ANTIGENS (US 11,975,064) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- 1 term has ended since Aug 23, 2026
- Oct 30 US 10,111,967 Complexes of RNA and Cationic Peptides for Transfection and for Immunostimulation · lapsed on the fee record
What they patent
The largest of its 58 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,434,154 | Composition for Treating Prostate Cancer (PCa) In force · High confidence | In force | High confidence | |
| US 11,421,038 | RNA-Coded Antibody In force · High confidence | In force | High confidence | |
| US 10,441,653 | Nucleic Acid Comprising GlXmGn as an Immune-Stimulating Agent/Adjuvant In force · Medium confidence | In force | Medium confidence | |
| US 8,968,746 | Complexation of Nucleic Acids with Disulfide-Crosslinked Cationic Components for Transfection and Immunostimulation In force · High confidence | In force | High confidence | |
| US 9,234,013 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Protein In force · High confidence | In force | High confidence | |
| US 9,839,697 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Protein In force · Medium confidence | In force | Medium confidence | |
| US 10,010,592 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Tumour Antigen In force · Medium confidence | In force | Medium confidence | |
| US 10,232,024 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Allergenic Antigen or an Autoimmune Self-Antigen In force · Medium confidence | In force | Medium confidence | |
| US 10,653,799 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Protein In force · Medium confidence | In force | Medium confidence | |
| US 11,110,156 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Tumour Antigen In force · High confidence | In force | High confidence |
Also on record, not counted in the 131: 15 patents in force now held by others · 31 patents ended · 87 applications pending · 137 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.